by Lori Solomon Long-term treatment of adolescents with moderate-to-severe atopic dermatitis (AD) with upadacitinib is safe and effective through 76 weeks, according to a study published online Oct. 23 in JAMA Dermatology. Amy S. Paller, M.D., from the Northwestern University Feinberg School of Medicine in Chicago, and colleagues evaluated the efficacy and adverse events of upadacitinib in adolescent patients with...
Tag: <span>Upadacitinib</span>
Post
Upadacitinib in moderate to severe atopic dermatitis: high doses produce added benefit for adults
INSTITUTE FOR QUALITY AND EFFICIENCY IN HEALTH CARE Upadacinib is a new drug for the treatment of adults and adolescents aged 12 years and older with moderate to severe atopic dermatitis who are candidates for systemic therapy. In an early benefit assessment, the German Institute for Quality and Efficiency in Health Care (IQWiG) has now...